Study to Evaluate the Safety and Efficacy of CJ-30060 in Hypertensive Patients With Hyperlipidemia

A Double-blind, Randomized, Multi-center Phase III Clinical Trial to Evaluate the Safety and Efficacy of CJ-30060 Compared With Amlodipine/Valsartan Combination Therapy and Valsartan/Rosuvastatin Combination Therapy in Hypertensive Patients With Hyperlipidemia

To evaluate the safety and efficacy of CJ-30060 compared with amlodipine/valsartan combination therapy and valsartan/rosuvastatin combination therapy in hypertensive patients with hyperlipidemia

Inclusion Criteria:

• Aged between 19 and 74 years
• Patient with dyslipidemia and hypertension

Exclusion Criteria:

• At screening, siSBP ≥ 200 mmHg or siDBP ≥ 120mmHg or LDL-C > 250mg/dL or TG ≥ 400mg/dL
• At screening, siSBP difference is ≥ 20 mmHg or siDBP difference is ≥10 mmHg
• Secodary hypertension
• Type I or uncontrolled diabetes mellitus (HbA1c ≥ 9 %)